Agile Therapeutics, Inc.
AGRX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 80% | 165.4% | 447.5% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 54.2% | 37.2% | -161.4% | 62.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -64.6% | -233.6% | -1,583.3% | -6,471% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -73.8% | -233.5% | -1,867.5% | -7,301.2% |
| EPS Diluted | -6.71 | -58.79 | -63,115.49 | -1,291.56 |
| % Growth | 88.6% | 99.9% | -4,786.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |